AFP
IONS icon

Ausdal Financial Partners’s Ionis Pharmaceuticals IONS Stock Holding History

Ausdal Financial Partners’s Portfolio IONS Stock Details IONS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-36
Closed -$2K – 616
2015
Q4 		$2K Buy
+36
New +$1.94K ﹤0.01% 1219

Other funds holding IONS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Ausdal Financial Partners's IONS Position: Q1 2016 in Review

Ausdal Financial Partners sold out of Ionis Pharmaceuticals (IONS) in Q1 2016, closing a stake of 36 shares — an estimated $2K sold.

Ausdal Financial Partners first reported a position in IONS in Q4 2015 and held it in 1 quarter. The position peaked at $2K in Q4 2015. 314 funds tracked by Wall St. Rank hold IONS as of Q1 2016.

  • Ausdal Financial Partners reported no remaining Ionis Pharmaceuticals position as of Q1 2016 after selling out during the quarter.
  • Ausdal Financial Partners sold 36 Ionis Pharmaceuticals shares in Q1 2016, an estimated $2K.
  • Ausdal Financial Partners first reported a position in Ionis Pharmaceuticals in Q4 2015 and held it in 1 quarter.
  • Ausdal Financial Partners's Ionis Pharmaceuticals position peaked at $2K in Q4 2015.
  • 314 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q1 2016.

Based on Ausdal Financial Partners's 13F filing for Q1 2016, filed 5 May 2016.